ALX Oncology Holdings Inc.

About ALX Oncology Holdings Inc.

ALX Oncology is a clinical-stage biopharmaceutical company focused on advancing therapies that boost the immune system to treat cancer. Their mission is to expand possibilities for patients by developing novel approaches to optimize current and future standards of cancer care.

Products & Services

Evorpacept:A lead therapeutic candidate with the potential to become a cornerstone therapy in immuno-oncology, aimed at unleashing the full power of the immune system for cancer treatment.

Specialties

Immuno-oncology Cancer therapies Immune system enhancement

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 150000000 MR: - FA: approximately $150 million FAN: 150000000	D: 2026-01-30 FD: 2026-01-30	12 investors
2	RT: Public Offering T: - FT: Public Offering	A: 63200000 MR: - FA: 63.2 million FAN: 63200000	D: 2023-10-10 FD: 2023-10-10	5 investors

Underwritten Offering Latest

2026-01-30

$150.0M

12 investors (Pro only)

Public Offering 2023-10-10

$63.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Keith Flaherty

Chair

C

Charles M. Baum

Chief Executive Officer

C

Corey Goodman

Chairman and Cofounder

R

Rekha Hemrajani

Member of the Board of Directors

S

Scott Garland

Member of the Board of Directors

J

Jason Lettmann

Chief Executive Officer

View 10 more team members with Pro

Unlock Full Team Directory

Recent News